ArticleInternational journal of molecular medicine2020
[Comment] COVID‑19 vaccine safety.
Article in International journal of molecular medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The long COVID research literature.Frontiers in research metrics and analytics · 2023Pooled it
- COVID-19 Vaccine-Related Thrombosis: A Systematic Review and Exploratory Analysis.Frontiers in immunology · 2021Pooled it
- Article
- Safety profile of inactivated COVID-19 vaccine in indonesian adults.Vaccine: X · 2023Article
- Role of vaccine in fighting the variants of COVID-19.Chaos, solitons, and fractals · 2023Article
- The Difference of COVID-19 Vaccination Attitude, Preventive Measures and Knowledge of SARS-COV-2 Between Diabetic Patients and Healthy Citizens in China.Journal of multidisciplinary healthcare · 2023Article
- The associations between COVID-19 vaccination and psychological disorders among healthcare workers in China.Journal of affective disorders · 2022Article
- Nirmatrelvir-remdesivir association for non-hospitalized adults with COVID-19, point of view.Inflammopharmacology · 2022Article
- Multiple evanescent white dot syndrome following BNT162b2 mRNA COVID-19 vaccination.American journal of ophthalmology case reports · 2022Article
- Adverse effects following COVID-19 vaccination in Iran.BMC infectious diseases · 2022Article
- Review
- Flare of adult-onset Still's disease following mRNA COVID-19 vaccination: a case report and review of literature.Clinical rheumatology · 2022Review
- Molecular docking and dynamics studies of Nicotinamide Riboside as a potential multi-target nutraceutical against SARS-CoV-2 entry, replication, and transcription: A new insight.Journal of molecular structure · 2022Article
- Targeting TNF-α for COVID-19: Recent Advanced and Controversies.Frontiers in public health · 2022Review
- Factors associated with side effects of COVID-19 vaccine in Indonesia.Clinical and experimental vaccine research · 2022Article
- Immunogenicity of Inactivated SARS-CoV-2 Vaccines in Patients With Rheumatoid Arthritis: A Case Series.Frontiers in public health · 2022Article
- COVID-19 Vaccines and Public Anxiety: Antibody Tests May Be Widely Accepted.Frontiers in public health · 2022Article
- Public reactions towards Covid-19 vaccination through twitter before and after second wave in India.Social network analysis and mining · 2022Article
- The pharmaceutical industry is dangerous to health. Further proof with COVID-19.Surgical neurology international · 2022Review
- COVID-19 vaccine hesitancy and willingness to pay: Emergent factors from a cross-sectional study in Nigeria.Vaccine: X · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In response to the SARS‑CoV‑2 outbreak, and the resulting COVID‑19 pandemic, a global competition to develop an anti‑COVID‑19 vaccine has ensued. The targeted time frame for initial vaccine deployment is late 2020. The present article examines whether short‑term, mid‑term, and long‑term vaccine safety can be achieved under such an accelerated schedule, given the myriad vaccine‑induced mechanisms that have demonstrated adverse effects based on previous clinical trials and laboratory research. It presents scientific evidence of potential pitfalls associated with eliminating critical phase II and III clinical trials, and concludes that there is no substitute currently available for long‑term human clinical trials to ensure long‑term human safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.